Meningioma

1. Ostrom QT, Price M, Neff C, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2016-2020. Neuro Oncol. 2023 Oct 4;25(12 suppl 2):iv1-99.[Abstract][Full Text]

2. ​World Health Organization Classification of Tumours Editorial Board. WHO classification of tumours of the central nervous system. 5th Edition. France: IARC; 2021.

3. Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021 Aug 2;23(8):1231-51.[Abstract][Full Text]

4. Rogers L, Gilbert M, Vogelbaum MA. Intracranial meningiomas of atypical (WHO grade II) histology. J Neurooncol. 2010 Sep;99(3):393-405.[Abstract]

5. Bowers DC, Moskowitz CS, Chou JF, et al. Morbidity and mortality associated with meningioma after cranial radiotherapy: a report from the Childhood Cancer Survivor Study. J Clin Oncol. 2017 May 10;35(14):1570-76.[Abstract][Full Text]

6. Withrow DR, Anderson H, Armstrong GT, et al. Pooled analysis of meningioma risk following treatment for childhood cancer. JAMA Oncol. 2022 Dec 1;8(12):1756-64.[Abstract][Full Text]

7. Casey DL, Vogelius IR, Brodin NP, et al. Risk of subsequent neoplasms in childhood cancer survivors after radiation therapy: a PENTEC comprehensive review. Int J Radiat Oncol Biol Phys. 2024 Jun 1;119(2):640-54.[Abstract]

8. Heymer EJ, Hawkins MM, Winter DL, et al. Risk of subsequent gliomas and meningiomas among 69,460 5-year survivors of childhood and adolescent cancer in Europe: the PanCareSurFup study. Br J Cancer. 2024 Apr;130(6):976-86.[Abstract][Full Text]

9. Wiemels J, Wrensch M, Claus EB. Epidemiology and etiology of meningioma. J Neurooncol. 2010 Sep;99(3):307-14.[Abstract][Full Text]

10. Lee E, Grutsch J, Persky V, et al. Association of meningioma with reproductive factors. Int J Cancer. 2006 Sep 1;119(5):1152-7.[Abstract][Full Text]

11. Sughrue ME, Kane AJ, Shangari G, et al. Prevalence of previous extracranial malignancies in a series of 1228 patients presenting with meningioma. J Neurosurg. 2010 Nov;113(5):1115-21.[Abstract]

12. Degeneffe A, De Maertelaer V, De Witte O, et al. The association between meningioma and breast cancer: a systematic review and meta-analysis. JAMA Netw Open. 2023 Jun 1;6(6):e2318620.[Abstract][Full Text]

13. Shahin MN, Magill ST, Dalle Ore CL, et al. Fertility treatment is associated with multiple meningiomas and younger age at diagnosis. J Neurooncol. 2019 May;143(1):137-44.[Abstract][Full Text]

14. Weill A, Nguyen P, Labidi M, et al. Use of high dose cyproterone acetate and risk of intracranial meningioma in women: cohort study. BMJ. 2021 Feb 3;372:n37.[Abstract][Full Text]

15. Lee KS, Zhang JJY, Kirollos R, et al. A systematic review and meta-analysis of the association between cyproterone acetate and intracranial meningiomas. Sci Rep. 2022 Feb 4;12(1):1942.[Abstract][Full Text]

16. Yelehe M, Klein M, El Aridi L, et al. Adverse effects of gender-affirming hormonal therapy in transgender persons: Assessing reports in the French pharmacovigilance database. Fundam Clin Pharmacol. 2022 Dec;36(6):1115-24.[Abstract][Full Text]

17. Lee YS, Lee YS. Molecular characteristics of meningiomas. J Pathol Transl Med. 2020 Jan;54(1):45-63.[Abstract][Full Text]

18. Ragel BT, Jensen RL, Couldwell WT. Inflammatory response and meningioma tumorigenesis and the effect of cyclooxygenase-2 inhibitors. Neurosurg Focus. 2007;23(4):E7.[Abstract][Full Text]

19. Phillips LE, Koepsell TD, van Belle G, et al. History of head trauma and risk of intracranial meningioma: population-based case-control study. Neurology. 2002 Jun 25;58(12):1849-52.[Abstract]

20. Kuan AS, Chen YT, Teng CJ, et al. Risk of meningioma in patients with head injury: a nationwide population-based study. J Chin Med Assoc. 2014 Sep;77(9):457-62.[Abstract][Full Text]

21. Buerki RA, Horbinski CM, Kruser T, et al. An overview of meningiomas. Future Oncol. 2018 Sep;14(21):2161-77.[Abstract][Full Text]

22. Ron E, Modan B, Boice JD, Jr, et al. Tumors of the brain and nervous system after radiotherapy in childhood. N Engl J Med. 1988 Oct 20;319(16):1033-9.[Abstract]

23. Preston-Martin S, Henderson BE, Bernstein L. Medical and dental x rays as risk factors for recently diagnosed tumors of the head. Natl Cancer Inst Monogr. 1985 Dec:69:175-9.[Abstract]

24. Claus EB, Calvocoressi L, Bondy ML, et al. Dental x-rays and risk of meningioma. Cancer. 2012 Sep 15;118(18):4530-7.[Abstract][Full Text]

25. Hemminki K, Li X, Collins VP. Parental cancer as a risk factor for brain tumors (Sweden). Cancer Causes Control. 2001 Apr;12(3):195-9.[Abstract]

26. Antinheimo J, Sankila R, Carpen O, et al. Population-based analysis of sporadic and type 2 neurofibromatosis-associated meningiomas and schwannomas. Neurology. 2000 Jan 11;54(1):71-6.[Abstract]

27. Watson MA, Gutmann DH, Peterson K, et al. Molecular characterization of human meningiomas by gene expression profiling using high-density oligonucleotide microarrays. Am J Pathol. 2002 Aug;161(2):665-72.[Abstract][Full Text]

28. Custer BS, Koepsell TD, Mueller BA. The association between breast carcinoma and meningioma in women. Cancer. 2002 Mar 15;94(6):1626-35.[Abstract][Full Text]

29. Lopez-Rivera V, Zhu P, Dono A, et al. Increased risk of subsequent meningioma among women with malignant breast cancer. World Neurosurg. 2020 Jul;139:e271-85.[Abstract]

30. Le Rhun E, Weller M. Sex-specific aspects of epidemiology, molecular genetics and outcome: primary brain tumours. ESMO Open. 2020 Nov;5(suppl 4):e001034.[Abstract][Full Text]

31. Hortobágyi T, Bencze J, Murnyák B, et al. Pathophysiology of meningioma growth in pregnancy. Open Med (Wars). 2017 Jul 13:12:195-200.[Abstract][Full Text]

32. Agopiantz M, Carnot M, Denis C, et al. Hormone receptor expression in meningiomas: a systematic review. Cancers (Basel). 2023 Feb 3;15(3):980.[Abstract][Full Text]

33. Portet S, Banor T, Bousquet J, et al. New insights into expression of hormonal receptors by meningiomas. World Neurosurg. 2020 Aug;140:e87-96.[Abstract]

34. Claus EB, Black PM, Bondy ML, et al. Exogenous hormone use and meningioma risk: what do we tell our patients? Cancer. 2007 Aug 1;110(3):471-6.[Abstract][Full Text]

35. Korhonen K, Raitanen J, Isola J, et al. Exogenous sex hormone use and risk of meningioma: a population-based case-control study in Finland. Cancer Causes Control. 2010 Dec;21(12):2149-56.[Abstract]

36. Roland N, Neumann A, Hoisnard L, et al. Use of progestogens and the risk of intracranial meningioma: national case-control study. BMJ. 2024 Mar 27;384:e078078.[Abstract][Full Text]

37. Champeaux-Depond C, Weller J, Froelich S, et al. Cyproterone acetate and meningioma: a nationwide-wide population based study. J Neurooncol. 2021 Jan;151(2):331-38.[Abstract]

38. Hoisnard L, Laanani M, Passeri T, et al. Risk of intracranial meningioma with three potent progestogens: A population-based case-control study. Eur J Neurol. 2022 Sep;29(9):2801-9.[Abstract][Full Text]

39. Voormolen EHJ, Champagne PO, Roca E, et al. Intracranial meningiomas decrease in volume on magnetic resonance imaging after discontinuing progestin. Neurosurgery. 2021 Jul 15;89(2):308-14.[Abstract]

40. Bernat AL, Oyama K, Hamdi S, et al. Growth stabilization and regression of meningiomas after discontinuation of cyproterone acetate: a case series of 12 patients. Acta Neurochir (Wien). 2015 Oct;157(10):1741-6.[Abstract]

41. Reuter G, Potorac I, de Herdt C, et al. Recommendations on the management of meningioma and sex hormone therapy: the results of a collaborative effort between neurosurgical, endocrine and gynecological societies. Brain Spine. 2025;5:104154.[Abstract][Full Text]

42. Wrensch M, Minn Y, Chew T, et al. Epidemiology of primary brain tumors: current concepts and review of the literature. Neuro Oncol. 2002 Oct;4(4):278-99.[Abstract][Full Text]

43. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: central nervous system cancers [internet publication].[Full Text]

44. American College of Radiology. ACR appropriateness criteria: brain tumors. 2024 [internet publication].[Full Text]

45. Szychot E, Goodden J, Whitfield G, et al. Children's Cancer and Leukaemia Group (CCLG): review and guidelines for the management of meningioma in children, teenagers and young adults. Br J Neurosurg. 2020 Apr;34(2):142-53.[Abstract]

46. Magill ST, Young JS, Chae R, et al. Relationship between tumor location, size, and WHO grade in meningioma. Neurosurg Focus. 2018 Apr;44(4):E4.[Abstract][Full Text]

47. Kernick DP, Ahmed F, Bahra A, et al. Imaging patients with suspected brain tumour: guidance for primary care. Br J Gen Pract. 2008 Dec;58(557):880-5.[Abstract][Full Text]

48. Ogasawara C, Philbrick BD, Adamson DC. Meningioma: a review of epidemiology, pathology, diagnosis, treatment, and future directions. Biomedicines. 2021 Mar 21;9(3):319.[Abstract][Full Text]

49. Nakasu S, Fukami T, Nakajima M, et al. Growth pattern changes of meningiomas: long-term analysis. Neurosurgery. 2005 May;56(5):946-55.[Abstract]

50. Goldbrunner R, Stavrinou P, Jenkinson MD, et al. EANO guideline on the diagnosis and management of meningiomas. Neuro Oncol. 2021 Nov 2;23(11):1821-34.[Abstract][Full Text]

51. Prasad RN, Perlow HK, Bovi J, et al. (68)Ga-DOTATATE PET: the future of meningioma treatment. Int J Radiat Oncol Biol Phys. 2022 Jul 15;113(4):868-71.[Abstract][Full Text]

52. Perlow HK, Siedow M, Gokun Y, et al. (68)Ga-DOTATATE PET-based radiation contouring creates more precise radiation volumes for patients with meningioma. Int J Radiat Oncol Biol Phys. 2022 Jul 15;113(4):859-65.[Abstract]

53. Hadi I, Biczok A, Terpolilli N, et al. Multimodal therapy of cavernous sinus meningioma: Impact of surgery and (68)Ga-DOTATATE PET-guided radiation therapy on tumor control and functional outcome. Neurooncol Adv. 2021 Jan-Dec;3(1):vdab114.[Abstract][Full Text]

54. Louis D, Scheithauer B, Budka H, et al. Meningiomas. In: Kleihues P, Cavenee W, editors. World Health Organization classification of tumours: pathology and genetics: tumours of the nervous system. Lyon, France: IARC Press, 2000.

55. Englot DJ, Magill ST, Han SJ, et al. Seizures in supratentorial meningioma: a systematic review and meta-analysis. J Neurosurg. 2016 Jun;124(6):1552-61.[Abstract][Full Text]

56. Louis DN, Ohgaki H, Westler OD, et al (eds). World Health Organization classification of tumours of the central nervous system. Lyon, France: IARC; 2007.

57. Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016 Jun;131(6):803-20.[Abstract][Full Text]

58. Sahm F, Aldape KD, Brastianos PK, et al. cIMPACT-NOW update 8: clarifications on molecular risk parameters and recommendations for WHO grading of meningiomas. Neuro Oncol. 2025 Feb 10;27(2):319-30.[Abstract][Full Text]

59. Simpson D. The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psychiatry. 1957 Feb;20(1):22-39.[Abstract]

60. Komotar RJ, Starke RM, Raper DM, et al. Endoscopic endonasal versus open transcranial resection of anterior midline skull base meningiomas. World Neurosurg. 2012 May-Jun;77(5-6):713-24.[Abstract]

61. Clark AJ, Jahangiri A, Garcia RM, et al. Endoscopic surgery for tuberculum sellae meningiomas: a systematic review and meta-analysis. Neurosurg Rev. 2013 Jul;36(3):349-59.[Abstract]

62. Kotecha RS, Pascoe EM, Rushing EJ, et al. Meningiomas in children and adolescents: a meta-analysis of individual patient data. Lancet Oncol. 2011 Dec;12(13):1229-39.[Abstract]

63. Martz N, Salleron J, Dhermain F, et al. Target volume delineation for radiotherapy of meningiomas: an ANOCEF consensus guideline. Radiat Oncol. 2023 Jul 5;18(1):113.[Abstract][Full Text]

64. Sheehan J, Pikis S, Islim AI, et al. An international multicenter matched cohort analysis of incidental meningioma progression during active surveillance or after stereotactic radiosurgery: the IMPASSE study. Neuro Oncol. 2022 Jan 5;24(1):116-24.[Abstract][Full Text]

65. Nakamura M, Roser F, Michel J, et al. The natural history of incidental meningiomas. Neurosurgery. 2003 Jul;53(1):62-70.[Abstract]

66. Sughrue ME, Rutkowski MJ, Aranda D, et al. Treatment decision making based on the published natural history and growth rate of small meningiomas. J Neurosurg. 2010 Nov;113(5):1036-42.[Abstract]

67. Firsching RP, Fischer A, Peters R, et al. Growth rate of incidental meningiomas. J Neurosurg. 1990 Oct;73(4):545-7.[Abstract]

68. Go RS, Taylor BV, Kimmel DW. The natural history of asymptomatic meningiomas in Olmsted County, Minnesota. Neurology. 1998 Dec;51(6):1718-20.[Abstract]

69. Herscovici Z, Rappaport Z, Sulkes J, et al. Natural history of conservatively treated meningiomas. Neurology. 2004 Sep 28;63(6):1133-4.[Abstract]

70. Olivero WC, Lister JR, Elwood PW. The natural history and growth rate of asymptomatic meningiomas: a review of 60 patients. J Neurosurg. 1995 Aug;83(2):222-4.[Abstract]

71. Yano S, Kuratsu J. Indications for surgery in patients with asymptomatic meningiomas based on an extensive experience. J Neurosurg. 2006 Oct;105(4):538-43.[Abstract]

72. Yoneoka Y, Fujii Y, Tanaka R. Growth of incidental meningiomas. Acta Neurochir (Wien). 2000;142(5):507-11.[Abstract]

73. Islim AI, Millward CP, Piper RJ, et al. External validation and recalibration of an incidental meningioma prognostic model - IMPACT: protocol for an international multicentre retrospective cohort study. BMJ Open. 2022 Jan 18;12(1):e052705.[Abstract][Full Text]

74. Islim AI, Kolamunnage-Dona R, Mohan M, et al. A prognostic model to personalize monitoring regimes for patients with incidental asymptomatic meningiomas. Neuro Oncol. 2020 Feb 20;22(2):278-89.[Abstract][Full Text]

75. Marcus HJ, Price SJ, Wilby M, et al. Radiotherapy as an adjuvant in the management of intracranial meningiomas: are we practising evidence-based medicine? Br J Neurosurg. 2008 Aug;22(4):520-8.[Abstract]

76. Marchetti M, Sahgal A, De Salles AAF, et al. Stereotactic radiosurgery for intracranial noncavernous sinus benign meningioma: International Stereotactic Radiosurgery Society systematic review, meta-analysis and practice guideline. Neurosurgery. 2020 Oct 15;87(5):879-90.[Abstract][Full Text]

77. Sughrue ME, Rutkowski MJ, Aranda D, et al. Factors affecting outcome following treatment of patients with cavernous sinus meningiomas. J Neurosurg. 2010 Nov;113(5):1087-92.[Abstract]

78. Lee CC, Trifiletti DM, Sahgal A, et al. Stereotactic radiosurgery for benign (World Health Organization Grade I) cavernous sinus meningiomas-International Stereotactic Radiosurgery Society (ISRS) practice guideline: a systematic review. Neurosurgery. 2018 Dec 1;83(6):1128-42.[Abstract]

79. Corniola MV, Roche PH, Bruneau M, et al. Management of cavernous sinus meningiomas: consensus statement on behalf of the EANS skull base section. Brain Spine. 2022 Jan 21:2:100864.[Abstract][Full Text]

80. Mair MJ, Berghoff AS, Brastianos PK, et al. Emerging systemic treatment options in meningioma. J Neurooncol. 2023 Jan;161(2):245-58.[Abstract][Full Text]

81. Palmisciano P, Haider AS, Balasubramanian K, et al. The role of cesium-131 brachytherapy in brain tumors: a scoping review of the literature and ongoing clinical trials. J Neurooncol. 2022 Aug;159(1):117-33.[Abstract]

82. Magill ST, Schwartz TH, Theodosopoulos PV, et al. Brachytherapy for meningiomas. Handb Clin Neurol. 2020;170:303-7.[Abstract]

83. Kondziolka D, Levy EI, Niranjan A, et al. Long-term outcomes after meningioma radiosurgery: physician and patient perspectives. J Neurosurg. 1999 Jul;91(1):44-50.[Abstract]

84. Machein MR, Plate KH. VEGF in brain tumors. J Neurooncol. 2000 Oct-Nov;50(1-2):109-20.[Abstract]

85. Preusser M, Hassler M, Birner P, et al. Microvascularization and expression of VEGF and its receptors in recurring meningiomas: pathobiological data in favor of anti-angiogenic therapy approaches. Clin Neuropathol. 2012 Sep-Oct;31(5):352-60.[Abstract]

86. Nayak L, Iwamoto FM, Rudnick JD, et al. Atypical and anaplastic meningiomas treated with bevacizumab. J Neurooncol. 2012 Aug;109(1):187-93.[Abstract]

87. Lou E, Sumrall AL, Turner S, et al. Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series. J Neurooncol. 2012 Aug;109(1):63-70.[Abstract][Full Text]

88. Andrae N, Kirches E, Hartig R, et al. Sunitinib targets PDGF-receptor and Flt3 and reduces survival and migration of human meningioma cells. Eur J Cancer. 2012 Aug;48(12):1831-41.[Abstract][Full Text]

89. Kaley TJ, Wen P, Schiff D, et al. Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma. Neuro Oncol. 2015 Jan;17(1):116-21.[Abstract]

90. Raheja A, Colman H, Palmer CA, et al. Dramatic radiographic response resulting in cerebrospinal fluid rhinorrhea associated with sunitinib therapy in recurrent atypical meningioma: case report. J Neurosurg. 2017 Nov;127(5):965-70.[Abstract]

91. Raizer JJ, Grimm SA, Rademaker A, et al. A phase II trial of PTK787/ZK 222584 in recurrent or progressive radiation and surgery refractory meningiomas. J Neurooncol. 2014 Mar;117(1):93-101.[Abstract]

92. Sherman WJ, Raizer JJ. Chemotherapy: What is its role in meningioma? Expert Rev Neurother. 2012 Oct;12(10):1189-95; quiz 1196.[Abstract][Full Text]

93. Chamberlain MC. Adjuvant combined modality therapy for malignant meningiomas. J Neurosurg. 1996 May;84(5):733-6.[Abstract]

94. Ji Y, Rankin C, Grunberg S, et al. Double-blind phase III randomized trial of the antiprogestin agent mifepristone in the treatment of unresectable meningioma: SWOG S9005. J Clin Oncol. 2015 Dec 1;33(34):4093-8.[Abstract]

95. Goodwin JW, Crowley J, Eyre HJ, et al. A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a Southwest Oncology Group study. J Neurooncol. 1993 Jan;15(1):75-7.[Abstract]

96. Schulz S, Pauli SU, Handel M, et al. Immunohistochemical determination of five somatostatin receptors in meningioma reveals frequent overexpression of somatostatin receptor subtype sst2A. Clin Cancer Res. 2000 May;6(5):1865-74.[Abstract][Full Text]

97. Schulz C, Mathieu R, Kunz U, et al. Treatment of unresectable skull base meningiomas with somatostatin analogs. Neurosurg Focus. 2011 May;30(5):E11.[Abstract]

98. Chamberlain MC, Glantz MJ, Fadul CE. Recurrent meningioma: salvage therapy with long-acting somatostatin analogue. Neurology. 2007 Sep 4;69(10):969-73.[Abstract]

99. Arena S, Barbieri F, Thellung S, et al. Expression of somatostatin receptor mRNA in human meningiomas and their implication in in vitro antiproliferative activity. J Neurooncol. 2004 Jan;66(1-2):155-66.[Abstract]

100. Simó M, Argyriou AA, Macià M, et al. Recurrent high-grade meningioma: a phase II trial with somatostatin analogue therapy. Cancer Chemother Pharmacol. 2014 May;73(5):919-23.[Abstract]

101. Kaba SE, DeMonte F, Bruner JM, et al. The treatment of recurrent unresectable and malignant meningiomas with interferon alpha-2B. Neurosurgery. 1997 Feb;40(2):271-5.[Abstract]

102. Koper JW, Zwarthoff EC, Hagemeijer A, et al. Inhibition of the growth of cultured human meningioma cells by recombinant interferon-alpha. Eur J Cancer. 1991;27(4):416-9.[Abstract]

103. Wober-Bingol C, Wober C, Marosi C, et al. Interferon-alfa-2b for meningioma. Lancet. 1995 Feb 4;345(8945):331.[Abstract]

104. Chamberlain MC, Glantz MJ. Interferon-alpha for recurrent World Health Organization grade 1 intracranial meningiomas. Cancer. 2008 Oct 15;113(8):2146-51.[Abstract][Full Text]

105. Chamberlain MC. IFN-alpha for recurrent surgery- and radiation-refractory high-grade meningioma: a retrospective case series. CNS Oncol. 2013 May;2(3):227-35.[Abstract][Full Text]

106. Schrell UM, Rittig MG, Anders M, et al. Hydroxyurea for treatment of unresectable and recurrent meningiomas. I. Inhibition of primary human meningioma cells in culture and in meningioma transplants by induction of the apoptotic pathway. J Neurosurg. 1997 May;86(5):845-52.[Abstract]

107. Schrell UM, Rittig MG, Anders M, et al. Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea. J Neurosurg. 1997 May;86(5):840-4.[Abstract]

108. Ragel BT, Couldwell WT, Wurster RD, et al. Chronic suppressive therapy with calcium channel antagonists for refractory meningiomas. Neurosurg Focus. 2007;23(4):E10.[Abstract][Full Text]

109. Mason WP, Gentili F, Macdonald DR, et al. Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma. J Neurosurg. 2002 Aug;97(2):341-6.[Abstract]

110. Karsy M, Hoang N, Barth T, et al. Combined hydroxyurea and verapamil in the clinical treatment of refractory meningioma: human and orthotopic xenograft studies. World Neurosurg. 2016 Feb;86:210-9.[Abstract]

111. Jaaskelainen J, Haltia M, Servo A. Atypical and anaplastic meningiomas: radiology, surgery, radiotherapy, and outcome. Surg Neurol. 1986 Mar;25(3):233-42.[Abstract]

112. Mirimanoff RO, Dosoretz DE, Linggood RM, et al. Meningioma: analysis of recurrence and progression following neurosurgical resection. J Neurosurg. 1985 Jan;62(1):18-24.[Abstract]

113. Milker-Zabel S, Zabel A, Schulz-Ertner D, et al. Fractionated stereotactic radiotherapy in patients with benign or atypical intracranial meningioma: long-term experience and prognostic factors. Int J Radiat Oncol Biol Phys. 2005 Mar 1;61(3):809-16.[Abstract]

114. Pettersson-Segerlind J, Orrego A, Lönn S, et al. Long-term 25-year follow-up of surgically treated parasagittal meningiomas. World Neurosurg. 2011 Dec;76(6):564-71.[Abstract]

115. Wang JZ, Landry AP, Raleigh DR, et al. Meningioma: International Consortium on meningiomas consensus review on scientific advances and treatment paradigms for clinicians, researchers, and patients. Neuro Oncol. 2024 Oct 3;26(10):1742-80.[Abstract][Full Text]

116. Ownsworth T, Hawkes A, Steginga S, et al. A biopsychosocial perspective on adjustment and quality of life following brain tumor: a systematic evaluation of the literature. Disabil Rehabil. 2009;31(13):1038-55.[Abstract]

117. Sanai N, Sughrue ME, Shangari G, et al. Risk profile associated with convexity meningioma resection in the modern neurosurgical era. J Neurosurg. 2010 May;112(5):913-9.[Abstract]

118. Diluna ML, Bulsara KR. Surgery for petroclival meningiomas: a comprehensive review of outcomes in the skull base surgery era. Skull Base. 2010 Sep;20(5):337-42.[Abstract]

119. Roth P, Pace A, Le Rhun E, et al. Neurological and vascular complications of primary and secondary brain tumours: EANO-ESMO Clinical Practice Guidelines for prophylaxis, diagnosis, treatment and follow-up. Ann Oncol. 2021 Feb;32(2):171-82.[Abstract][Full Text]

120. Greenhalgh J, Weston J, Dundar Y, et al. Antiepileptic drugs as prophylaxis for postcraniotomy seizures. Cochrane Database Syst Rev. 2020 Apr 28;(4):CD007286.[Abstract][Full Text]

121. Tremont-Lukats IW, Ratilal BO, Armstrong T, et al. Antiepileptic drugs for preventing seizures in people with brain tumors. Cochrane Database Syst Rev. 2008 Apr 16;(2):CD004424.[Abstract][Full Text]

122. Fluss R, Kobets AJ, Inocencio JF, et al. The incidence of venous thromboembolism following surgical resection of intracranial and intraspinal meningioma. A systematic review and retrospective study. Clin Neurol Neurosurg. 2021 Feb;201:106460.[Abstract]

123. Sanford NN, Yeap BY, Larvie M, et al. Prospective, randomized study of radiation dose escalation with combined proton-photon therapy for benign meningiomas. Int J Radiat Oncol Biol Phys. 2017 Nov 15;99(4):787-96.[Abstract][Full Text]

124. McClelland S 3rd, Ciporen JN, Mitin T, et al. Long-term stroke risk of single-fraction photon-based stereotactic radiosurgery for meningioma. Clin Neurol Neurosurg. 2018 Oct;173:169-72.[Abstract]

125. Couldwell WT. Asymptomatic meningiomas. J Neurosurg. 2006 Oct;105(4):536-7.[Abstract]

126. Nguyen MP, Morshed RA, Dalle Ore CL, et al. Supervised machine learning algorithms demonstrate proliferation index correlates with long-term recurrence after complete resection of WHO grade I meningioma. J Neurosurg. 2023 Jan 1;138(1):86-94.[Abstract]

127. Lall RR, Lall RR, Smith TR, et al. Delayed malignant transformation of petroclival meningioma to chondrosarcoma after stereotactic radiosurgery. J Clin Neurosci. 2014 Jul;21(7):1225-8.[Abstract]

128. Osipov V, Ho KC, Krouwer HG, et al. Post-radiation dedifferentiation of meningioma into osteosarcoma. BMC Cancer. 2002 Dec 3:2:34.[Abstract][Full Text]

129. Rogers L, Barani I, Chamberlain M, et al. Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review. J Neurosurg. 2015 Jan;122(1):4-23.[Abstract]